Notes: September 21, 2023, Precipio, Inc. (the “Company”) filed a Certificate of Amendment to its Third Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of Delaware, pursuant to which the Company effected a 1-for-20 reverse stock split (the “Reverse Stock Split”) of its issued and outstanding common stock, par value $0.01 per share (the “Common Stock”). The Common Stock is anticipated to begin trading on a split-adjusted basis on Nasdaq at the market open on September 22, 2023. The trading symbol for the Common Stock will remain “PRPO.” Following the Reverse Stock Split, the CUSIP for the Company’s Common Stock will be 74019L602. <p> June 6, 2017 -- Transgenomic today announced its shareholders have approved the previously announced planed merger with Precipio Diagnostics. Upon completion of the transaction, privately held Precipio will become a wholly owned subsidiary of Transgenomic. Shares of the new firm, to be called Precipio Inc., will be listed on the Nasdaq under ticker symbol PRPO. Precipio Founder and CEO Ilan Danieli will be the CEO of the new firm.